Adcendo ApS has appointed Michael Pehl as chief executive to oversee development of its portfolio of antibody-drug conjugates (ADC) for cancers. He joins the Danish company from GEMoaB GmbH of Germany where he also served as CEO. Before that, he headed Immunomedics Inc as CEO, leading the development of the ADC sacituzumab govitecan, which was given an accelerated approval in the US in 2020 for triple negative breast cancer.
Adcendo announced the appointment on 7 July 2021.
Copyright 2021 Evernow Publishing Ltd